A citation-based method for searching scientific literature

Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli, Jessica Read, Peter Langmuir, Anderson J Ryan, Martin J Schlumberger. J Clin Oncol 2012
Times Cited: 839







List of co-cited articles
820 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Lindsey M Kelly, Guillermo Barila, Pengyuan Liu, Viktoria N Evdokimova, Sumita Trivedi, Federica Panebianco, Manoj Gandhi, Sally E Carty, Steven P Hodak, Jianhua Luo,[...]. Proc Natl Acad Sci U S A 2014
164
4

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Cecile N Chougnet, Isabelle Borget, Sophie Leboulleux, Christelle de la Fouchardiere, Françoise Bonichon, Lise Criniere, Patricia Niccoli, Stéphane Bardet, Olivier Schneegans, Sylvie Zanetta,[...]. Thyroid 2015
33
12

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
J W B de Groot, B A Zonnenberg, P Quarles van Ufford-Mannesse, M M de Vries, T P Links, C J M Lips, E E Voest. J Clin Endocrinol Metab 2007
127
4

BRAF mutation in thyroid cancer.
M Xing. Endocr Relat Cancer 2005
930
4

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki,[...]. Cancer Sci 2015
73
5

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
417
4

Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Marie-Hélène Massicotte, Maryse Brassard, Médéric Claude-Desroches, Isabelle Borget, Françoise Bonichon, Anne-Laure Giraudet, Christine Do Cao, Cécile N Chougnet, Sophie Leboulleux, Eric Baudin,[...]. Eur J Endocrinol 2014
71
5

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
Cristina Rodríguez-Antona, Judith Pallares, Cristina Montero-Conde, Lucia Inglada-Pérez, Esmeralda Castelblanco, Iñigo Landa, Susanna Leskelä, Luis J Leandro-García, Elena López-Jiménez, Rocío Letón,[...]. Endocr Relat Cancer 2010
85
4

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
4

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
169
4

Central role of RET in thyroid cancer.
Massimo Santoro, Francesca Carlomagno. Cold Spring Harb Perspect Biol 2013
65
6


Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
L D Locati, A Piovesan, C Durante, M Bregni, M G Castagna, S Zovato, M Giusti, T Ibrahim, E Puxeddu, G Fedele,[...]. Eur J Cancer 2019
42
9


Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
Yann Godbert, Bénédicte Henriques de Figueiredo, Françoise Bonichon, Frédéric Chibon, Isabelle Hostein, Gaëlle Pérot, Camille Dupin, Agnès Daubech, Genevieve Belleannée, Audrey Gros,[...]. J Clin Oncol 2015
72
5

Definition and management of radioactive iodine-refractory differentiated thyroid cancer.
Martin Schlumberger, Marcia Brose, Rosella Elisei, Sophie Leboulleux, Markus Luster, Fabian Pitoia, Furio Pacini. Lancet Diabetes Endocrinol 2014
168
4

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
888
4

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
4

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
494
4

New drugs for medullary thyroid cancer: new promises?
Christine Spitzweg, John C Morris, Keith C Bible. Endocr Relat Cancer 2016
15
26

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
D J Marsh, D L Learoyd, S D Andrew, L Krishnan, R Pojer, A L Richardson, L Delbridge, C Eng, B G Robinson. Clin Endocrinol (Oxf) 1996
156
4

Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997-2014: A Nationwide Study.
Jes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, Kirstine Stochholm, Per Løgstrup Poulsen, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Sten Schytte, Stefano Christian Londero, Henrik Baymler Pedersen,[...]. Thyroid 2019
26
15

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Beth Chasen, Erik Mittra, Pamela L Kunz, Matthew H Kulke, Heather Jacene,[...]. N Engl J Med 2017
4

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Qingling Huang, Valentina E Schneeberger, Noreen Luetteke, Chengliu Jin, Roha Afzal, Mikalai M Budzevich, Rikesh J Makanji, Gary V Martinez, Tao Shen, Lichao Zhao,[...]. Mol Cancer Ther 2016
51
7

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
C Eng, D P Smith, L M Mulligan, M A Nagai, C S Healey, M A Ponder, E Gardner, G F Scheumann, C E Jackson, A Tunnacliffe. Hum Mol Genet 1994
439
4

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.
Erika Grossrubatscher, Giuseppe Fanciulli, Luca Pes, Franz Sesti, Carlotta Dolci, Federica de Cicco, Annamaria Colao, Antongiulio Faggiano, Nike Group. J Clin Med 2020
9
44

Guidelines for diagnosis and therapy of MEN type 1 and type 2.
M L Brandi, R F Gagel, A Angeli, J P Bilezikian, P Beck-Peccoz, C Bordi, B Conte-Devolx, A Falchetti, R G Gheri, A Libroia,[...]. J Clin Endocrinol Metab 2001
4

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Luca Mologni, Sara Redaelli, Andrea Morandi, Ivan Plaza-Menacho, Carlo Gambacorti-Passerini. Mol Cell Endocrinol 2013
62
6

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
Yongkun Sun, Wei Niu, Feng Du, Chunxia Du, Shuting Li, Jinwan Wang, Li Li, Fengqing Wang, Yu Hao, Chuan Li,[...]. J Hematol Oncol 2016
192
4

Lenvatinib for Anaplastic Thyroid Cancer.
Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura,[...]. Front Oncol 2017
85
4

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
4

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Winette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, Dong-Wan Kim, Binh Bui-Nguyen, Paolo G Casali, Patrick Schöffski, Massimo Aglietta, Arthur P Staddon, Yasuo Beppu,[...]. Lancet 2012
4

Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Luciana Audi de Castroneves, Marcelo Vailati Negrão, Ricardo Miguel Costa de Freitas, Carla Papadia, José Viana Lima, Julia T Fukushima, Eduardo Furquim Simão, Marco Aurélio Vamondes Kulcsar, Marcos Roberto Tavares, Alexander Augusto de Lima Jorge,[...]. Thyroid 2016
26
15

Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.
E de Graaff, S Srinivas, C Kilkenny, V D'Agati, B S Mankoo, F Costantini, V Pachnis. Genes Dev 2001
178
4

Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex.
Angela Amoresano, Mariarosaria Incoronato, Gianluca Monti, Piero Pucci, Vittorio de Franciscis, Laura Cerchia. Cell Signal 2005
36
11


MEN2A-RET-induced cellular transformation by activation of STAT3.
J J Schuringa, K Wojtachnio, W Hagens, E Vellenga, C H Buys, R Hofstra, W Kruijer. Oncogene 2001
63
6

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim,[...]. Endocrinol Metab (Seoul) 2020
5
80

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.
Diana Bradford, Erin Larkins, Sirisha L Mushti, Lisa Rodriguez, Amy M Skinner, Whitney S Helms, Lauren S L Price, Jeanne Fourie Zirkelbach, Yangbing Li, Jiang Liu,[...]. Clin Cancer Res 2021
20
20

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
Fabienne Iten, Beat Müller, Christian Schindler, Christoph Rochlitz, Daniel Oertli, Helmut R Mäcke, Jan Müller-Brand, Martin A Walter. Clin Cancer Res 2007
91
4

Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.
Iván Plaza-Menacho, Karin Barnouin, Kerry Goodman, Rubén J Martínez-Torres, Annabel Borg, Judith Murray-Rust, Stephane Mouilleron, Phillip Knowles, Neil Q McDonald. Mol Cell 2014
45
8

Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Gilbert J Cote, Caitlin Evers, Mimi I Hu, Elizabeth G Grubbs, Michelle D Williams, Tao Hai, Dzifa Y Duose, Michal R Houston, Jacquelin H Bui, Meenakshi Mehrotra,[...]. J Clin Endocrinol Metab 2017
36
11

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
V Subbiah, T Shen, M Tetzlaff, A Weissferdt, L A Byers, T Cascone, A Behrang, F Meric-Bernstam, B H M Mooers, S M Rothenberg,[...]. Ann Oncol 2021
8
50

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.
Janice Kim, Diana Bradford, Erin Larkins, Lee H Pai-Scherf, Somak Chatterjee, Pallavi S Mishra-Kalyani, Emily Wearne, Whitney S Helms, Amal Ayyoub, Youwei Bi,[...]. Clin Cancer Res 2021
11
36

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
613
4

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
34
11

REToma: a cancer subtype with a shared driver oncogene.
Takashi Kohno, Junya Tabata, Takashi Nakaoku. Carcinogenesis 2020
20
20

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
71
5

Structure and physiology of the RET receptor tyrosine kinase.
Carlos F Ibáñez. Cold Spring Harb Perspect Biol 2013
94
4

RET/PTC rearrangement in thyroid tumors.
Yuri E Nikiforov. Endocr Pathol 2002
301
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.